The U.S. Food and Drug Administration (FDA) has approved the medication Leucovorin for the treatment of a rare genetic condition, but officials clarified that the approval does not extend to the treatment of Autism Spectrum Disorder.
Leucovorin, also known as folinic acid, has long been used in medical settings for specific conditions, including reducing the side effects of certain chemotherapy treatments and addressing folate deficiencies. The new approval allows its use for a rare genetic disorder that affects the body’s ability to properly process folate, an essential vitamin involved in DNA synthesis and brain development.
Health experts say the decision is based on clinical evidence showing that leucovorin can help patients with the genetic condition restore proper metabolic function. However, the FDA emphasized that current scientific data does not support approving the drug as a treatment for autism.
In recent years, some researchers and advocacy groups have explored whether folinic acid supplements might benefit certain children with autism, particularly those with folate metabolism abnormalities. While some small studies have suggested potential improvements in language or behavior in specific cases, regulators say the evidence remains limited and inconsistent.
The FDA’s statement is intended to clarify the approved medical use of leucovorin and to prevent confusion about its role in treating autism. Officials noted that additional research would be required before the drug could be considered for broader neurological or developmental conditions.
Medical professionals continue to advise families to consult healthcare providers before pursuing alternative or off-label treatments for autism. The agency also reiterated its commitment to supporting research that could lead to safe and effective therapies for people with autism spectrum disorder.
